381 related articles for article (PubMed ID: 10376616)
1. Zidovudine, didanosine, and zalcitabine in the treatment of HIV infection: meta-analyses of the randomised evidence. HIV Trialists' Collaborative Group.
Lancet; 1999 Jun; 353(9169):2014-25. PubMed ID: 10376616
[TBL] [Abstract][Full Text] [Related]
2. Zidovudine (AZT) versus AZT plus didanosine (ddI) versus AZT plus zalcitabine (ddC) in HIV infected adults.
Darbyshire J; Foulkes M; Peto R; Duncan W; Babiker A; Collins R; Hughes M; Peto T; Walker A
Cochrane Database Syst Rev; 2000; 2000(2):CD002038. PubMed ID: 10796851
[TBL] [Abstract][Full Text] [Related]
3. Zidovudine (AZT) versus AZT plus didanosine (ddI) versus AZT plus zalcitabine (ddC) in HIV infected adults.
Darbyshire J; Foulkes M; Peto R; Duncan W; Babiker A; Collins R; Hughes M; Peto T; Walker A
Cochrane Database Syst Rev; 2000; (3):CD002038. PubMed ID: 10908523
[TBL] [Abstract][Full Text] [Related]
4. Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trial.
Lancet; 1997 May; 349(9063):1413-21. PubMed ID: 9164314
[TBL] [Abstract][Full Text] [Related]
5. Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Delta Coordinating Committee.
Lancet; 1996 Aug; 348(9023):283-91. PubMed ID: 8709686
[TBL] [Abstract][Full Text] [Related]
6. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team.
Hammer SM; Katzenstein DA; Hughes MD; Gundacker H; Schooley RT; Haubrich RH; Henry WK; Lederman MM; Phair JP; Niu M; Hirsch MS; Merigan TC
N Engl J Med; 1996 Oct; 335(15):1081-90. PubMed ID: 8813038
[TBL] [Abstract][Full Text] [Related]
7. A randomized, controlled, double-blind study comparing the survival benefit of four different reverse transcriptase inhibitor therapies (three-drug, two-drug, and alternating drug) for the treatment of advanced AIDS. AIDS Clinical Trial Group 193A Study Team.
Henry K; Erice A; Tierney C; Balfour HH; Fischl MA; Kmack A; Liou SH; Kenton A; Hirsch MS; Phair J; Martinez A; Kahn JO
J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Dec; 19(4):339-49. PubMed ID: 9833742
[TBL] [Abstract][Full Text] [Related]
8. Immediate versus deferred zidovudine (AZT) in asymptomatic or mildly symptomatic HIV infected adults.
Darbyshire J; Foulkes M; Peto R; Duncan W; Babiker A; Collins R; Hughes M; Peto T; Walker A
Cochrane Database Syst Rev; 2000; (2):CD002039. PubMed ID: 10796852
[TBL] [Abstract][Full Text] [Related]
9. Survival in HIV-infected patients who have received zidovudine: comparison of combination therapy with sequential monotherapy and continued zidovudine monotherapy. Multicenter AIDS Cohort Study Group.
Graham NM; Hoover DR; Park LP; Stein DS; Phair JP; Mellors JW; Detels R; Saah AJ
Ann Intern Med; 1996 Jun; 124(12):1031-8. PubMed ID: 8633816
[TBL] [Abstract][Full Text] [Related]
10. Immediate versus deferred zidovudine (AZT) in asymptomatic or mildly symptomatic HIV infected adults.
Darbyshire J; Foulkes M; Peto R; Duncan W; Babiker A; Collins R; Hughes M; Peto T; Walker A
Cochrane Database Syst Rev; 2000; (3):CD002039. PubMed ID: 10908524
[TBL] [Abstract][Full Text] [Related]
11. Zidovudine alone or in combination with didanosine or zalcitabine in HIV-infected patients with the acquired immunodeficiency syndrome or fewer than 200 CD4 cells per cubic millimeter. Investigators for the Terry Beirn Community Programs for Clinical Research on AIDS.
Saravolatz LD; Winslow DL; Collins G; Hodges JS; Pettinelli C; Stein DS; Markowitz N; Reves R; Loveless MO; Crane L; Thompson M; Abrams D
N Engl J Med; 1996 Oct; 335(15):1099-106. PubMed ID: 8813040
[TBL] [Abstract][Full Text] [Related]
12. Zidovudine, didanosine, or both as the initial treatment for symptomatic HIV-infected children. AIDS Clinical Trials Group (ACTG) Study 152 Team.
Englund JA; Baker CJ; Raskino C; McKinney RE; Petrie B; Fowler MG; Pearson D; Gershon A; McSherry GD; Abrams EJ; Schliozberg J; Sullivan JL
N Engl J Med; 1997 Jun; 336(24):1704-12. PubMed ID: 9182213
[TBL] [Abstract][Full Text] [Related]
13. Relevance of AIDS treatment with two nucleoside analogues alone.
Weidle PJ; Mbidde E; Djomand G; Lackritz EM
Lancet; 1999 Jun; 353(9169):1989-90. PubMed ID: 10376610
[No Abstract] [Full Text] [Related]
14. Zidovudine monotherapy versus zidovudine plus zalcitabine combination therapy in HIV-positive persons with CD4 cell counts 300-500 cells/mm3: a double-blind controlled trial. The M50003 Study Group Coordinating and Writing Committee.
Moyle GJ; Bouza E; Antunes F; Smith D; Harris R; Warburg M; Walker M
Antivir Ther; 1997 Dec; 2(4):229-36. PubMed ID: 11327442
[TBL] [Abstract][Full Text] [Related]
15. [Effect of treatment with nucleoside analogues in subjects with primary genotypic resistance to zidovudine].
Leal M; Caruz A; Rey C; Lissen E
Med Clin (Barc); 1996 Nov; 107(19):755. PubMed ID: 9082095
[No Abstract] [Full Text] [Related]
16. [Anti-HIV therapy (1987-1994): from nothing to confusion].
Lissen E
Med Clin (Barc); 1995 Apr; 104(12):463-7. PubMed ID: 7739285
[No Abstract] [Full Text] [Related]
17. The impact of zidovudine compared with didanosine on health status and functioning in persons with advanced HIV infection and a varying duration of prior zidovudine therapy. AIDS Clinical Trials Group 116/117 Study Group.
Bozzette SA; Kanouse DE; Duan N; Berry S; Richman DD
Antivir Ther; 1996 Jan; 1(1):21-32. PubMed ID: 11322256
[TBL] [Abstract][Full Text] [Related]
18. Evidence for prolonged clinical benefit from initial combination antiretroviral therapy: Delta extended follow-up.
Delta Coordinating Committee
HIV Med; 2001 Jul; 2(3):181-8. PubMed ID: 11737399
[TBL] [Abstract][Full Text] [Related]
19. Meta-analysis of five randomized controlled trials comparing continuation of zidovudine versus switching to didanosine in HIV-infected individuals.
Raboud JM; Montaner JS; Rae S; Kahn J; Hammer SM; Katzenstein DA; Pavia A; Dolin R; Hughes MD; Cross A; Beltangady M; Gatell J; Dunkle L; Smaldone L
Antivir Ther; 1997 Dec; 2(4):237-47. PubMed ID: 11327443
[TBL] [Abstract][Full Text] [Related]
20. Virologic and immunologic benefits of initial combination therapy with zidovudine and zalcitabine or didanosine compared with zidovudine monotherapy. Wellcome Resistance Study Collaborative Group.
Schooley RT; Ramirez-Ronda C; Lange JM; Cooper DA; Lavelle J; Lefkowitz L; Moore M; Larder BA; St Clair M; Mulder JW; McKinnis R; Pennington KN; Harrigan PR; Kinghorn I; Steel H; Rooney JF
J Infect Dis; 1996 Jun; 173(6):1354-66. PubMed ID: 8648207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
